Mirvaso® (brimonidine) the First and Only Treatment Targeting the Facial Redness of Rosacea Approved by the European Commission
Lausanne, Switzerland (ots/PRNewswire) - - Galderma portfolio expands to offer a fast onset and long-acting alpha-2 adrenergic receptor agonist - Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today announced that the European Commission has granted Marketing Authorisation in ...